ADP-ribosylation : An emerging direction for disease treatment
Copyright © 2024 Elsevier B.V. All rights reserved..
ADP-ribosylation (ADPr) is a dynamically reversible post-translational modification (PTM) driven primarily by ADP-ribosyltransferases (ADPRTs or ARTs), which have ADP-ribosyl transfer activity. ADPr modification is involved in signaling pathways, DNA damage repair, metabolism, immunity, and inflammation. In recent years, several studies have revealed that new targets or treatments for tumors, cardiovascular diseases, neuromuscular diseases and infectious diseases can be explored by regulating ADPr. Here, we review the recent research progress on ART-mediated ADP-ribosylation and the latest findings in the diagnosis and treatment of related diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:94 |
|---|---|
| Enthalten in: |
Ageing research reviews - 94(2024) vom: 15. Feb., Seite 102176 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Yu-Ting [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ADP Ribose Transferases |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.arr.2023.102176 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366323938 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366323938 | ||
| 003 | DE-627 | ||
| 005 | 20240214233027.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.arr.2023.102176 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM366323938 | ||
| 035 | |a (NLM)38141734 | ||
| 035 | |a (PII)S1568-1637(23)00335-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Yu-Ting |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ADP-ribosylation |b An emerging direction for disease treatment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a ADP-ribosylation (ADPr) is a dynamically reversible post-translational modification (PTM) driven primarily by ADP-ribosyltransferases (ADPRTs or ARTs), which have ADP-ribosyl transfer activity. ADPr modification is involved in signaling pathways, DNA damage repair, metabolism, immunity, and inflammation. In recent years, several studies have revealed that new targets or treatments for tumors, cardiovascular diseases, neuromuscular diseases and infectious diseases can be explored by regulating ADPr. Here, we review the recent research progress on ART-mediated ADP-ribosylation and the latest findings in the diagnosis and treatment of related diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ADP-ribosylation | |
| 650 | 4 | |a Cardiovascular diseases | |
| 650 | 4 | |a Disease treatment | |
| 650 | 4 | |a PARP inhibitor | |
| 650 | 4 | |a Tumor | |
| 650 | 7 | |a ADP Ribose Transferases |2 NLM | |
| 650 | 7 | |a EC 2.4.2.- |2 NLM | |
| 650 | 7 | |a Proteins |2 NLM | |
| 700 | 1 | |a Che, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Hong-Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Hong-Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Yi-Zhou |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Jiang-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Qi-Zhu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ageing research reviews |d 2002 |g 94(2024) vom: 15. Feb., Seite 102176 |w (DE-627)NLM119138735 |x 1872-9649 |7 nnns |
| 773 | 1 | 8 | |g volume:94 |g year:2024 |g day:15 |g month:02 |g pages:102176 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.arr.2023.102176 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 94 |j 2024 |b 15 |c 02 |h 102176 | ||